TriSalus Life Sciences Future Growth
Future criteria checks 2/6
TriSalus Life Sciences is forecast to grow earnings and revenue by 3% and 30.2% per annum respectively while EPS is expected to grow by 36.6% per annum.
Key information
3.0%
Earnings growth rate
36.6%
EPS growth rate
Biotechs earnings growth | 24.8% |
Revenue growth rate | 30.2% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 16 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 57 | -61 | -56 | N/A | 2 |
12/31/2025 | 42 | -45 | -39 | N/A | 2 |
12/31/2024 | 29 | -45 | -48 | N/A | 2 |
3/31/2024 | 22 | -68 | N/A | N/A | N/A |
12/31/2023 | 19 | -63 | -51 | -50 | N/A |
9/30/2023 | 16 | -52 | -50 | -50 | N/A |
6/30/2023 | 15 | -59 | -34 | -33 | N/A |
3/31/2023 | 13 | -51 | -33 | -32 | N/A |
12/31/2022 | 12 | -50 | -33 | -32 | N/A |
9/30/2022 | 12 | -32 | -30 | -28 | N/A |
12/31/2021 | 8 | -29 | -24 | -23 | N/A |
12/31/2020 | 5 | -32 | -16 | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TLSI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TLSI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TLSI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TLSI's revenue (30.2% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: TLSI's revenue (30.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TLSI's Return on Equity is forecast to be high in 3 years time